Scalper1 News
Big-cap biotech Biogen (BIIB) said Wednesday that it had licensed a drug candidate from Japan’s Mitsubishi Tanabe Pharma for treating multiple sclerosis and other autoimmune diseases, sending Biogen stock rising. The candidate, MT-1303, is an oral S1P modulator, similar to Novartis’ (NVS) MS drug Gilenya and RPC-1063, the late-stage drug candidate that Celgene (CELG) just acquired with its buyout of Receptos. Data from the phase two trial in Scalper1 News
Scalper1 News